The adalimumab market is expected to witness a negative CAGR during the forecast period 2020-2026. Adalimumab is a biological drug sold by AbbVie Inc., under the brand name Humira for the treatment of various diseases including arthritis, Crohn's disease, ulcerative colitis, and others. The company was witnessing a significant growth until the patent of the drugs doesn’t expire in the US and Europe. In 2019, Humira generated revenue of $19.1 billion as compared to $19.9 billion in 2018.
Browse the full report description Global Adalimumab Market Size, Share & Trends Analysis Report, By Disease (Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis, and others), By Type (Branded and Generic) and Forecast, 2020-2026 at https://www.omrglobal.com/industry-reports/adalimumab-market
The US is the major market of the adalimumab market. As in 2019, around 77% of the total Humira revenue was generated from the US which was around $14.8 billion. It is expected that even when the biosimilar will be introduced to the US market, the market penetration of Humira will be considerably high. AbbVie Inc. has lost its patent in December 2016 in the US, however, due to multiple agreements with other biosimilar manufacturing companies, AbbVie is expected to maintain a monopoly in the country. Amgen Inc. was the first company to get approval for a biosimilar for adalimumab in September 2016 however in September 2017, the company got into an agreement with AbbVie Inc., to delay the launch of the drug till 31st January 2023. In May 2019, AbbVie Inc. collaborated with Boehringer Ingelheim International GmbH, not to manufacturer adalimumab biosimilar till 1st July 2023. Similarly in October 2018, Novartis AG got the FDA approval for Hyrimoz (adalimumab-adaz) however it will start the marketing only after 30th September 2023.
Europe is expected to show a modest growth rate during the forecast period. The European adalimumab market is in the transition phase from branded biological drugs to the biosimilar. Both Humira and its biosimilars are available in the European market. After the patent expiration of Humira in Europe, four biosimilars are available in the market that are Amgen’s Amgevita, Biogen’s Imraldi, Sandoz’s Hyrimoz, and Terumo Corp.’s Hulio. All these companies are offering a huge discount to remain competitive in the market. For instance, in order to maintain a monopoly in the adalimumab market, AbbVie Inc., is offering high discounts to the hospitals. The company has offered a discount of up to 89% to the Dutch health care system as Amegen was offering a discount of around 85% to the Santeon group (an alliance of seven large hospitals in the Netherlands). Moreover, AbbVie Inc. offers a discount to a hospital only when the hospital buys branded products for all the patients. Some instances were witnessed when some hospitals in the Netherlands wants to purchase Humira only for the patients who can’t be shifted to the biosimilar medicine.
Asia-Pacific is expected to showcase significant growth during the forecast period. The increase in patient pool and rising healthcare expenditure is expected to provide significant market growth during the forecast period. Humira is not approved in the Indian market however a number of biosimilars of it are available in the country. Cadila Healthcare Ltd. had launched the adalimumab biosimilar in December 2014 under brand name Exemptia. Torrent Pharmaceutical Ltd. launched the adalimumab biosimilar under the brand name Adfrar in 2016. Other companies offering adalimumab in India include Reliance Life Sciences Pvt. Ltd., Hetero Healthcare Ltd., and so on. Bio-Thera Solutions Ltd. and Innovent Biologics, Inc. are some of the major companies working in the adalimumab market in China whereas Fujifilm Kyowa Kirin Biologics Co. Ltd. is a major Japanese company working in the market.
Global Adalimumab Market- Segmentation
By Disease
By Type
Global Adalimumab Market– Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To
learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/adalimumab-market